期刊文献+

老药的安全性不容忽视

Safety of the old drugs should not be ignored
原文传递
导出
摘要 老药一般认为是上市时间较早,在临床使用多年,且被医药工作者和公众所了解的药品。老药的安全性尚存在很多未知、未解问题。老药的一些不良反应可能目前还不十分清楚;老药在特殊人群中应用的安全性还需要长期监测;老药许多不良反应发生机制研究需加强,大多数不良反应缺乏特异性诊断的生物标记物及有效的防治措施;老药说明书中不良反应相关内容需要不断完善,许多临床用药的安全性问题还有待制定规范的专家共识和指南。 Old drugs are generally considered as drugs that have been on the market for many years and are well known by medical workers and the public.There are still many unsolved problems about the safety of older drugs.Some adverse reactions of old drugs may not be fully understood at present,the safety of their application in special populations still needs long-term monitoring,the study on mechanism of many adverse reactions of old drugs need to be strengthened,and most adverse reactions lack specific diagnostic biomarkers and effective prevention and treatment measures.The adverse reaction content in the old drug labels needs to be continuously improved,and many safety issues in drug application still require standardized expert consensus and guidance.
作者 蔡晧东 Cai Haodong(Adverse Drug Reactions Journal Agency,Beijing 100053,China)
出处 《药物不良反应杂志》 CSCD 2024年第3期129-132,共4页 Adverse Drug Reactions Journal
关键词 药物相关副作用和不良反应 安全性 患者安全 Drug-related side effects and adverse reactions Safety Patient safety
  • 相关文献

参考文献11

二级参考文献88

  • 1Gao, Xiao-Zhong,Qiao, Xiu-Li,Song, Wen-Chong,Wang, Xiao-Feng,Liu, Feng.Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication[J].World Journal of Gastroenterology,2010,16(34):4357-4362. 被引量:20
  • 2徐婷,吴丹.海舒必与稳可信存在配伍禁忌[J].山东医药,2007,47(23):22-22. 被引量:1
  • 3Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses[ J]. Clin Ther, 2003, 25 ( 2 ) : 342 -395.
  • 4Hall VC, El-Aghary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma[J]. J Am Acad Dermatol, 2003, 48(4) :548- 552.
  • 5Clark TE, Edom N, Larson J, et al. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing [ J ]. Drug Saf, 2001, 24 (2) : 87- 117.
  • 6Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients [ J ]. J Invest Dermatol, 2002, 119 (5) :987-1020.
  • 7Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term ( > lyr) thalidomide therapy in patients with multiple myeloma [ J ]. Eur J naematol, 2005, 74 ( 3 ) : 212-216.
  • 8Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide : patterns of occurrence and the role of electrophysiologic monitoring[ J ]. J Clin Oncol, 2006, 24 ( 27 ) : 4507- 4514.
  • 9Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus [ J ]. Autoimmunity, 2005, 38 ( 7 ) : 549- 555.
  • 10Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus : a 65 series of Brazilian patients [ J ]. Lupus, 2005, 14(6) :434-439.

共引文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部